mexiletine (mexitil) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Mexiletine is a non-selective voltage-gated sodium channel blocker which belongs to the Class IB anti-arrhythmic group of medicines. It is used to treat heart arrhythmias. Mexiletine is also used to treat refractory pain and muscle stiffness resulting in myotonic dystrophy or myotonia congenita. Mexiletine was approved for commercial use in 1985 under the brand name Mexitil, but most marketing efforts have since been discontinued. There has been a continued effort to identify other therapeutic use cases and a number of clinical trials have been conducted including ALS and chronic pain from amputation.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.7429 - $1.6479
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-(2',6'-dimethylphenoxy)-2-aminopropane | 1-(2,6-dimethylphenoxy)-2-propanamine | (+-)-1-(2,6-dimethylphenoxy)propan-2-amine | 1-methyl-2-(2,6-xylyloxy)ethanamine | (2rs)-1-(2,6-dimethylphenoxy)-2-aminopropane | dl-mexiletine | ko-1173 cl | ko-1173-cl | mexetil | mexiletina | mexiletine | (+/-)-mexiletine | mexilétine | mexiletine hcl | mexiletine hydrochloride | mexiletin hcl | mexiletin hydrochloride | mexiletinum | mexitil | mexitil p.l. | (rs)-mexiletine

Organizations (48)

Research & Development (36)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (30)

Approved Indications (2)


 

Arrhythmias, Cardiac (approved 1985)

Muscle Cramp (approved 1985)

Experimental Indications - Clinical Trial Phases 1-4 (29)


 

Amputation, Surgical (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 4)

Arrhythmias, Cardiac (Phase 3)

Blepharospasm (Phase 2)

Cardiotoxicity (Phase 1)

Cardiovascular Diseases (Phase 3)

Charcot-Marie-Tooth Disease (Phase 2)

Chronic Pain (Phase 2)

Death, Sudden, Cardiac (Phase 3)

Diabetic Neuropathies (Phase 3)

Dystonia (Phase 2)

Heart Arrest (Phase 3)

Heart Diseases (Phase 3)

HIV Infections (Phase 2)

Irritable Bowel Syndrome (Phase 1)

Myocardial Infarction (Phase 3)

Myotonia (Phase 3)

Myotonia Congenita (Phase 3)

Myotonic Disorders (Phase 3)

Myotonic Dystrophy (Phase 3)

Pain (Phase 3)

Paresthesia (Phase 3)

Peripheral Nervous System Diseases (Phase 2)

Pharmacokinetics (Phase 1)

Polyradiculoneuropathy (Phase 4)

Spasm (Phase 2)

Tachycardia (Phase 4)

Tachycardia, Ventricular (Phase 3)

Ventricular Fibrillation (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial Organizations: 36

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue